University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...
University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut ...
Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), reducing the price target ...
BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...
12d
C the Signs, the creator of an Artificial Intelligence (AI)-based platform to identify patients at risk of cancer at the ...
A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic ...
News Medical on MSN13h
Machine learning tool predicts cancer treatment response based on genetic mutationsA groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes-insights that could help doctors ...
A study published in Scientific Reports found that cannabidiol (CBD) disrupts lipid metabolism and induces apoptosis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback